Gould Robert J 4

What Happened

• Robert J. Gould, a director of Fulcrum Therapeutics (FULC), sold 15,000 shares on February 2, 2026 in an open-market transaction. The weighted-average sale price was $10.72 per share, for total proceeds of approximately $160,857. This was a sale (not a purchase), which is often routine insider liquidity rather than an expressed positive signal.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely).
• Shares sold: 15,000; weighted-average price reported: $10.72; total value: ~$160,857.
• Price range: shares were sold in multiple trades between $10.48 and $11.10 (reporting person can provide a breakdown on request).
• Footnote: Sales were made under a Rule 10b5-1 trading plan adopted August 1, 2025.
• Shares owned after the transaction: not disclosed in the provided summary of the filing.

Context

• 10b5-1 plans allow insiders to sell shares according to a pre-established plan; such sales are generally viewed as planned liquidity and provide less direct insight into the insider’s current view of the company. No option exercises, gifts, or other derivative actions were reported.